Marc Williams: -- put up the PowerPoint, that would be great.
It's been a real pleasure for Blackford and I, as we plan this get-together.
We were saying it's been in the planning stages for quite some time, and it's exciting that
it's actually going to be here.
A couple of housekeeping things: the agenda that is in your booklet, we'll be trying to
adhere to that very strictly so that we can make sure we make it to all the different
topics that we think are important.
Also by your seat, you'll notice a very important single sheet of paper that talks about the
Desiderata of Macy's and Welch [spelled phonetically], which I think is becoming sort of a -- perhaps
will be engraved in stone somewhere someday.
But, that is something that, as we have discussions, we'll probably refer back to these different
elements frequently.
So keep that handy so that you can keep track during the discussion.
The breakfast is over to the side.
Most of you have probably figured out that the restrooms are out and to the left.
This is being webcast, and there -- we know that there are a number of people that are
going to be on the webcast today.
So, in the discussion, it's going to be very important that, even if you have a voice as
loud as mine, which none of you do, to use your microphones, which are in front of you.
And there are two things related to the microphones.
One is when you press it, you will notice a red bar will come on.
When you're done making your comments, make sure that you turn it off again, because,
in most cases, if there are too many on, then it will close out anyone else.
We're going to try and -- it can be sometimes difficult in a room of this size to keep track
of everyone that wants to ask a question.
So just make sure you get somebody's attention, either Blackford or myself, or the moderators
for each of the different sessions.
Our moderators are all towards the end of the inner U there -- where hopefully we can
have pretty good sidelines.
I'm not going to go through the agenda too much other than to say that we will organize
it around five key questions.
But first of all, here's the objectives for this meeting, convening key thought leader.
So if you're here, you got a congratulations on being promoted to a key thought leader,
you can add that to your CV.
And genomic implementation and application of clinical decision support.
And what we really want to do today, is to compare our current assessment of the state
of genomic clinical decision support with what we may envision as an ideal state, and
then trying to find gaps, and strategies to close those gaps.
We want to identify and engage U.S. and international health IT initiatives that could support our
recommended strategies, and then define and prioritize a research agenda for genomic clinical
decision support.
And our key questions are going to be: is clinical decision support an essential element
in the successful implementation of genomic medicine?
And I think, to some degree, that's a, perhaps a rhetorical question for the group that's
convened around the table here.
So, we sort of answered -- that was asked and answered to some degree.
But, you know, some of the questions that underlie that, is genomic clinical decision
support, does it differ significantly from other types of decision support, and if so,
what are the key differences?
What is the ideal state, and how can the impact be defined and measured?
And so, this is going to be in the purview of our keynote speaker, Dan Masys, who will
get us off to a great start, in just a couple of minutes.
We will then have three sessions that are going to be primarily discussion around three
different issues that we identified as being fundamental.
What are data issues that impact genomic CDS; how do we manage knowledge for genomic CDS;
and what are the implementation issues surrounding genomic CDS?
And you'll see in the agenda that each of those has a separate breakout discussion.
Now it's not to say that there's no relationship between these, but I think what we'd wanted
to do is to focus so that we can derive some information that would be of utility for what
we're going to be doing tomorrow, which is, to really spend our half-day together to identify
and prioritize a potential research agenda for genomic clinical decision support.
So what I want to do in the last little bit of the introduction here, is to very quickly
go around the room and have everybody introduce themselves.
So, basically, this is name, rank, and serial number.
So give your name, and where you're from.
And, for those of you -- I think everybody knows -- maybe just in case -- I'm Marc Williams.
I'm the Director of the Genomic Medicine Institute at Geisinger Health System.
Then, we'll do the outer you.
Blackford Middleton: Good morning.
Blackford Middleton from Vanderbilt, and let me add my welcome to Marc's.
Thanks, everybody, for coming, and it looks like it'll be an exciting day and a half.
Kirk Wilhelmsen: Kirk Wilhelmsen, UNC and RENCI, I’m Director
of Bioinformatics at RENCI.
Lou Cress: Lou Cress.
I’m a Cinema Developer Team Lead and software architect, from Northwestern University.
Rex Chisholm: Rex Chisholm, Northwestern University.
Andrew Roden: Andrew Roden, Vanderbilt.
Josh Tenni: Josh Tenni, Vanderbilt.
Paul Dexter: Paul Dexter, Wiggin Street.
Glen Lee: Glen Lee, Indiana University.
Jamie Skipper: Jamie Skipper, ONC, that's the Office of the
National Coordinator for Health IT.
Nathan Helse: Nathan Helse, Inter Mountain Healthcare.
Si Loman: Si Loman, Inter Mountain Healthcare.
Brian Shirts: Brian Shirts at Laboratory Medicine of the
University of Washington.
Male Speaker: [inaudible], NIH, NHGRI.
Brandan Keating: Brendan Keating, University of Pennsylvania.
David Flannery: David Flannery, from American College of Medical
Genetics.
Male Speaker: And genomics.
[laughter]
Jason Vasse-Briggin: Jason Vasse-Briggin, Women's Hospital.
Heidi Ream: Heidi Ream, Partners HealthCare, and Harvard
Medical School.
Sandy Aranton: Sandy Aranton, Partners HealthCare.
Chris Shoot: Chris Shoot, Mayo Clinic.
Betsy Humphreys: Betsy Humphreys, National Library of Medicine.
Arjun Manrai: Arjun Manrai, Harvard Medical School.
Liz Worthy: Liz Worthy, Medical College of Wisconsin.
Derek Skulls: Derek Skulls, NHGRI.
Jean Jenkins: Jean Jenkins, NHGRI.
Jillian Belle: Jillian Belle, Moffitt Cancer Center.
Chris Wetherstran: Chris Wetherstran, NHGRI
Annie Kneels: Annie Kneels, NHGRI
Jackie Ojis: Jackie Ojis, NGHRI
Kristin Weitzel: Kristin Weitzel, University of Florida.
James Hoffman: James Hoffman, St. Jude Children's Research
Hospital.
Mark Hoffman: Mark Hoffman, University of Missouri, Kansas
City.
Leslie Biesecker: Leslie Biesecker, Intermural Research Program,
Genome Institute
Teri Manolio: Teri Manolio, Genome Institute
David Fence Demacker: David Fence Demacker, Virginia Commonwealth
University
Josh Peterson: Josh Peterson, Vanderbilt.
Dan Masys: Dan Masys, University of Washington.
Jim Ostell: Jim Ostell, MCBI.
Robert Freimuth: Bob Freimuth, Mayo Clinic.
Casey Overby: Casey Overby, University of Maryland.
Ken Kawamoto: Hi, I'm Ken Kawamoto.
I'm Associate CMIO at University of Utah, co-Chair the HL7 Clinical Decision Support
Work Group.
Brandon Welch: I am Brandon Welch from the Medical University
of South Carolina.
Suzanne Belinson: Suzanne Belinson, Blue Cross, Blue Shield
Association.
Alex Milsovich: Alex Milsovich, Molecular Human Genetics,
Baylor College of Medicine.
Adam Berger: Adam Berger, Institute of Medicine.
Marc Williams: Great, thank you all very much.
I should have mentioned, at the outset, that this meeting is being sponsored by the NHGRI.
And in particular, this is the seventh meeting that has been convened under a group called
the Genomic Medicine Working Group, of which we have several steering committee members,
Rex, Dan, myself.
We've convened a number of meetings on a diverse set of topics that we think are important
to move genomic medicine into the implementation space.
And this is the latest of these meetings.
They've been, I think, extremely interesting, have brought together a broad and diverse
group of stakeholders and there have been a lot of really good things that have emerged
from this, including several RFAs, specifically related to some topics that have been developed.
So, for example, the Ignite Program, which I know some of you are members of, was the
direct result of one of these meetings.
And even though it wasn't specifically under the auspices of the Genomic Medicine Working
Group, the ClinGen Project, which many of us are a part of, also came out of a large
meeting of this sort.
So I think this is something that has a lot of potential to really help those of us that
are trying to move this field forward develop some traction.
So, with that, I'm going to turn it over to my co-moderator, Blackford Middleton, who's
going to discuss the results of the survey that almost all of you filled out.
I think it's one of the highest response rates of a survey I have ever seen, so thank you
for that.
Blackford Middleton: Thanks very much, Marc.
[end of transcript]